A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais

By Nitayaphan S.   Khamboonruang C.   Sirisophana N.   Morgan P.   Chiu J.   Duliege A.-M.   Chuenchitra C.   Supapongse T.   Rungruengthanakit K.   deSouza M.   Mascola J.R.   Boggio K.   Ratto-Kim S.   Markowitz L.E.   Birx D.   Suriyanon V.   McNeil J.G.   Brown A.E.   Michael R.A.  

Vaccine, Vol. 18, Iss. 15, 2000-02 ,pp. : 1448-1455

Elsevier

Access to resources Recommend Favorite

Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials

By Gilbert P.B.   Chiu Y.-L.   Allen M.   Lawrence D.N.   Chapdu C.   Israel H.   Holman D.   Keefer M.C.   Wolff M.   Frey S.E.   NIAID HIV Vaccine Trials Network  

Vaccine, Vol. 21, Iss. 21, 2003-06 ,pp. : 2933-2947

Elsevier

Access to resources Recommend Favorite

Development of StaphVAX(TM), a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials

By Fattom A.I.   Horwith G.   Fuller S.   Propst M.   Naso R.  

Vaccine, Vol. 22, Iss. 7, 2004-02 ,pp. : 880-887

Elsevier

Access to resources Recommend Favorite

A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (Sao Goncalo do Amaranto, RN)

By da Silva V.O.   Borja-Cabrera G.P.   Correia Pontes N.N.   de Souza E.P.   Luz K.G.   Palatnik M.   Palatnik de Sousa C.B.  

Vaccine, Vol. 19, Iss. 9, 2000-12 ,pp. : 1082-1092

Elsevier

Access to resources Recommend Favorite

Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials

By Cornu C.   Yzebe D.   Leophonte P.   Gaillat J.   Boissel J.P.   Cucherat M.  

Vaccine, Vol. 19, Iss. 32, 2001-09 ,pp. : 4780-4790

Elsevier

Access to resources Recommend Favorite